Role of immunosuppression in the development of quinolone-resistant Escherichia coli spontaneous bacterial peritonitis and in the mortality of E. coli spontaneous bacterial peritonitis

Aliment Pharmacol Ther. 2003 Mar 1;17(5):695-701. doi: 10.1046/j.1365-2036.2003.01491.x.

Abstract

Background: Norfloxacin decreases the incidence of spontaneous bacterial peritonitis in cirrhotics, but promotes the appearance of quinolone-resistant Escherichia coli.

Aim: : To define the characteristics of quinolone-resistant E. coli spontaneous bacterial peritonitis.

Methods: E. coli-positive ascitic fluid cultures were identified during a 6-year period. Data on quinolone-sensitive and quinolone-resistant E. coli spontaneous bacterial peritonitis were compared.

Results: One hundred and two E. coli-positive ascitic fluid cultures were detected. Cirrhotics accounted for 67 cases. Spontaneous bacterial peritonitis was found in 47 of the 67 (70%) cases [35 (74%) caused by quinolone-sensitive and 12 (26%) caused by quinolone-resistant E. coli]. Norfloxacin prophylaxis was higher in the quinolone-resistant group (92% vs. 6%, P < 0.001). Compared with patients with quinolone-sensitive E. coli spontaneous bacterial peritonitis, those with quinolone-resistant E. coli spontaneous bacterial peritonitis showed a higher prevalence of associated immunosuppressive factors (immunosuppressive drugs, human immunodeficiency virus infection or cancer) (92% vs. 20%, P < 0.001). Steroid therapy was independently associated with quinolone-resistant E. coli spontaneous bacterial peritonitis (odds ratio, 49; 95% confidence interval, 3.4-699; P = 0.004). The Child-Pugh score (P = 0.03), immunosuppression (P = 0.02) and renal failure (P = 0.01) were independent predictors of E. coli spontaneous bacterial peritonitis-related mortality.

Conclusions: Associated immunosuppression is an important co-factor for the development of quinolone-resistant E. coli spontaneous bacterial peritonitis and for E. coli spontaneous bacterial peritonitis-related mortality.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Infective Agents / therapeutic use*
  • Ascitic Fluid / microbiology
  • Drug Resistance, Bacterial / immunology*
  • Escherichia coli Infections / drug therapy
  • Escherichia coli Infections / immunology*
  • Humans
  • Immune Tolerance
  • Immunosuppression Therapy
  • Immunosuppressive Agents / adverse effects
  • Liver Cirrhosis / complications*
  • Norfloxacin / therapeutic use*
  • Peritonitis / drug therapy
  • Peritonitis / immunology*
  • Peritonitis / microbiology

Substances

  • Anti-Infective Agents
  • Immunosuppressive Agents
  • Norfloxacin